Evidences for the Anti-panic Actions of Cannabidiol Vanessa P. Soares and Alline C. Campos Current Neuropharmacology, 2017, 15, 291-299 DOI : 10.2174/1570159X14666160509123955 Abstract : Background : Panic disorder (PD) is a disabling psychiatry condition that affects approximately 5% of the worldwide population. Currently, long-term selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for PD; however, the common side-effect profiles and drug interactions may provoke patients to abandon the treatment, leading to PD symptoms relapse. Cannabidiol (CBD) is the major non-psychotomimetic constituent of the Cannabis sativa plant with antianxiety properties that has been suggested as an alternative for treating anxiety disorders. The aim of the [...]
Lire la suiteCannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia : A Multicenter Randomized Controlled Trial Philip McGuire, F.R.C.Psych., F.Med.Sci., Philip Robson, M.R.C.P., F.R.C.Psych., Wieslaw Jerzy Cubala, M.D., Ph.D., Daniel Vasile, M.D., Ph.D., Paul Dugald Morrison, Ph.D., M.R.C.Psych., Rachel Barron, B.Vet.Med., M.R.C.V.S., Adam Taylor, Ph.D., Stephen Wright, F.R.C.P.(Edin), F.F.P.M. American Journal of Psychiatry, 2018, 175, 225–231. doi: 10.1176/appi.ajp.2017.17030325 Objective : Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. Method : In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 [...]
Lire la suiteCannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence Cathrin Rohleder, Juliane K. Müller, Bettina Lange and F. M. Leweke Frontiers in Pharmacology, 2016, Volume 7, Article 422. doi: 10.3389/fphar.2016.00422 There is urgent need for the development of mechanistically different and less side-effect prone antipsychotic compounds. The endocannabinoid system has been suggested to represent a potential new target in this indication. While the chronic use of cannabis itself has been considered a risk factor contributing to the development of schizophrenia, triggered by the phytocannabinoid delta-9-tetra-hydro-cannabinol (19-THC), cannabidiol, the second most important phytocannabinoid, appears to have no psychotomimetic potential. [...]
Lire la suiteTherapeutic Potential of Cannabinoids in Psychosis. Leweke F.M., Mueller J.K., Lange B., Rohleder C. Biological Psychiatry, 2016, 79, (7) 604-612. doi: 10.1016/j.biopsych.2015.11.018. Abstract Over recent years, the interest in the endocannabinoid system (ECS) as a new target for the treatment of schizophrenia has evolved. The ECS represents one of the most relevant neurotransmitter systems in the brain and mainly fulfills a homeostatic role in terms of neurotransmission but also with respect to inflammatory processes. Two main approaches to the modulation of endocannabinoid functioning have been chosen so far. First, the selective blockade or inverse agonism of the type 1 cannabinoid receptor has been tested for [...]
Lire la suiteChapter 97 - Cannabidiol for the Treatment of Drug Use Disorders R.G. dos SANTOS, J.E.C. HALLAK, W. ZUARDI, J.A. de SOUZA in "Handbook of Cannabis and Related Pathologies". "Biology, Pharmacology, Diagnosis, and Treatment", 2017, Pages 939-946 https://doi.org/10.1016/B978-0-12-800756-3.00113-7 Abstract The problematic use of psychoactive substances like alcohol, cannabis, cocaine, amphetamines, heroin, and nicotine carry a series of health, economic, and social costs to individuals and society. Although pharmacological treatments for alcohol, heroin, and nicotine abuse or dependence are available, there is no approved medication for the treatment of cannabis and stimulant dependence. Cannabidiol (CBD), a nonpsychotomimetic cannabinoid present in the cannabis plant, has anxiolytic, antipsychotic, antiepileptic, [...]
Lire la suiteCannabidiol and Canabis Use Disorder María S. García-Gutiérrez, Francisco Navarrete, Adrián Viudez-Martínez, Ani Gasparyan, Esther Caparrós, Jorge Manzanares Chapter, In book : "Cannabis Use Disorders", 2018, pp 31-42 DOI: 10.1007/978-3-319-90365-1_5 Abstract Cannabis use disorders (CUD) represent a serious public health problem in occidental societies. Despite their devastating social, health, and economic impact, to date no pharmacological treatment has been approved for the clinical management of cannabis dependence. Cannabidiol (CBD), one of the main compounds—together with Δ9-THC—present in the plant Cannabis sativa, has been reported to possess anxiolytic, antidepressant, and antipsychotic-like effects and neuroprotective properties. And, contrary to Δ9-THC, CBD does not appear to have addictive properties. Taken [...]
Lire la suiteUse of new and uncommon synthetic psychoactive drugs among a nationally representative sample in the United States, 2005–2017 Joseph J. Palamar & Austin Le Human Psychopharmacology Clinical and Experimental, 2019, e2690 DOI: 10.1002/hup.2690 Abstract Objectives : This study aims to examine patterns and first mentions of reported use of new or uncommon drugs across 13 years, among nationally representative samples in the United States. Methods : Participants (ages ≥12) in the National Surveys on Drug Use and Health (2005–2017, N = 730,418) were provided opportunities to type in names of new or uncommon drugs they had ever used that were not specifically queried. We examined self‐reported [...]
Lire la suiteApproche anthropologique de la dissociation et de ses dispositifs inducteurs Georges Lapassade DESS Ethnométhodologie et Informatique année universitaire 2004-2005 Résumé du séminaire de Georges Lapassade sur l’anthropologie de la dissociation 40 pp L'anthropologie religieuse, puis l'anthropologie psychologique1 ont contribué fortement au processus historique par lequel la notion de la dissociation, initialement issue de la psychopathologie, a fini par désigner un mécanisme psychobiologique normal et universel (Ludwig 1983). Pour contribuer à cette anthropologie la dissociation, je commencerai par l'étude de certaines pratiques chamaniques examinées du point de vue de la théorie de la conscience dissociée. J'examinerai ensuite la position qui consiste à rejeter cette analyse au motif [...]
Lire la suiteThe link between childhood trauma and dissociation in frequent users of classic psychedelics and dissociatives Sascha B. Thal, Judith K. Daniels & Henrik Jungaberle Journal of Substance Use, may 2019 https://doi.org/10.1080/14659891.2019.1614234 ABSTRACT Background : Childhood trauma severity is associated with the level of subsequent substance use as well as with the self-reported severity of dissociation. Classic psychedelics and dissociatives target neurotransmitter systems thought to be involved in the onset of dissociative symptoms and may evoke severe and long-lasting symptoms of depersonalization in some users. However, it is currently unclear whether drug use puts people with a history of childhood trauma at higher risk of developing [...]
Lire la suiteCANNABIS PEER REVIEW 1964-2016 Over 650 Peer Reviewed Reports & Studies On Cannabis A Free Jeff Prager Publication Health benefits, cancer fighting qualities and many other medicinal advantages can be attributed to the Cannabis Plant. Likewise, diseases and disorders are also related to smoking, vaping and ingesting components of the Cannabis Plant. Cannabis users should be aware and well informed regarding both the positive effects and the negative consequences of regular Cannabis use and this eBook accomplishes that goal by employing over 400 current peer reviewed reports and studies—their findings— with active hyper links to each report. A Free Jeff Prager No-Copyright Publication for [...]
Lire la suite